TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7611207

Group type: EXPERIMENTAL
Intervention: Cerulein (10-80 pmol/kg/h) with secretin background (1 CU/kg/h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 12
Study: 2243429

Group type: EXPERIMENTAL
Intervention: Colestipol-niacin therapy
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 321992

Group type: EXPERIMENTAL
Intervention: Amoxicillin and flucloxacillin combination
Number of subjects: 89

Group type: COMPARATOR
Intervention: Amoxicillin alone
Number of subjects: 89
Study: 31570210

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TTA) administered at three points during THA (n=55)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Saline solution as placebo (Control group, n=47)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid administration
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Higher preoperative hemoglobin level
Number of subjects: 102
Study: 27644229

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily
Number of subjects: 220

Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 220
Study: 25745075

Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 1499

Group type: COMPARATOR
Intervention: ICD
Number of subjects: 1499
Study: 23835333

Group type: EXPERIMENTAL
Intervention: Teplizumab
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study: 21593295

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg, three intravenous infusions)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 19319166

Group type: EXPERIMENTAL
Intervention: Teething
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Childcare attendance
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Having siblings aged less than 5 years
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Total illnesses
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Respiratory illness (RI)
Number of subjects: 225
Study: 15967694

Group type: EXPERIMENTAL
Intervention: ipratropium + theophylline (IP + THEO)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: formoterol + theophylline (FOR + THEO)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ipratropium + formoterol (IP + FOR)
Number of subjects: 60
Study: 12048323

Group type: COMPARATOR
Intervention: HI group (VO2max > 62.5 mL.kg‐1.min‐1)
Number of subjects: 12
Study: 10209977

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Number of subjects: 404

Group type: COMPARATOR
Intervention: Unvaccinated group
Number of subjects: 404
Study: 7843749

Group type: EXPERIMENTAL
Intervention: Irbesartan 25 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Irbesartan 100 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Irbesartan 1 mg
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 2236726

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 360853

Group type: EXPERIMENTAL
Intervention: Combined preoperative radiotherapy and surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 100
Study: 29545948

Group type: EXPERIMENTAL
Intervention: Daprodustat (100 mg) coadministered with pioglitazone or rosuvastatin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Daprodustat (25 mg) coadministered with trimethoprim
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trimethoprim (as a weak CYP2C8 inhibitor)
Number of subjects: 40
Study: 27417531

Group type: EXPERIMENTAL
Intervention: CARE+ Spanish intervention
Number of subjects: 494

Group type: COMPARATOR
Intervention: Risk assessment-only control
Number of subjects: 494
Study: 23570834

Group type: EXPERIMENTAL
Intervention: Individualized family planning messages and referrals provided by trained vaccinators
Number of subjects: 8892

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 8892
Study: 23765178

Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 20 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 40 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 60 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pasireotide LAR (all doses)
Number of subjects: 42
Study: 19910943

Group type: EXPERIMENTAL
Intervention: CR: 25% decrease in energy intake
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CREX: 12.5% CR + 12.5% increase in energy expenditure
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: LCD: low-calorie diet until 15% weight reduction followed by weight maintenance
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 18548292

Group type: EXPERIMENTAL
Intervention: One-visit indirect pulp treatment (IPT)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Two-visit indirect pulp treatment (IPT)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Direct complete excavation (DCE)
Number of subjects: 135
Study: 15708100

Group type: EXPERIMENTAL
Intervention: Once daily tobramycin
Number of subjects: 244

Group type: COMPARATOR
Intervention: Three-times daily tobramycin
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Once daily tobramycin (in children)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Three-times daily tobramycin (in children)
Number of subjects: 244
Study: 12372942

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 64.6 IU/kg in a single bolus at the start of dialysis
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard heparin (SH) 1,500 IU at the start of dialysis and 1,500 +/- 500 IU in continuous infusion
Number of subjects: 54
Study: 9502829

Group type: EXPERIMENTAL
Intervention: 0.1 mg of pergolide
Number of subjects: 32

Group type: COMPARATOR
Intervention: 2.5 mg of bromocriptine
Number of subjects: 32
Study: 7694914

Group type: EXPERIMENTAL
Intervention: Fluoxetine (N = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (N = 6)
Number of subjects: 12
Study: 2708001

Group type: EXPERIMENTAL
Intervention: Resorbable intraperitoneal mesh of polyglactin 910
Number of subjects: 100

Group type: COMPARATOR
Intervention: Externally applied polyamide fiber mesh
Number of subjects: 100
Study: 329825

Group type: EXPERIMENTAL
Intervention: Practolol (400 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 31711467

Group type: EXPERIMENTAL
Intervention: Social networking time
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Personality traits (emotional instability, extraversion, conscientiousness)
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Big Five personality traits
Number of subjects: 765
Study: 28711309

Group type: EXPERIMENTAL
Intervention: Scalpel-designed bevel needle (SB)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Triple bevel needle (TB)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Regular bevel needle (RB)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All needle types (SB, TB, RB)
Number of subjects: 150
Study: 25849646

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg daily) with NaCl supplementation (100 mmol/24 h)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Telmisartan (40 mg daily) with placebo
Number of subjects: 28
Study: 25166287

Group type: EXPERIMENTAL
Intervention: Comprehensive medication management services delivered postdischarge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 22559376

Group type: EXPERIMENTAL
Intervention: MAP with best masked MDTs
Number of subjects: 0

Group type: COMPARATOR
Intervention: MAP with worst masked MDTs
Number of subjects: 0
Study: 19387825

Group type: EXPERIMENTAL
Intervention: Wellness program focusing on stress management and problem solving
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broader wellness intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17498002

Group type: EXPERIMENTAL
Intervention: 22-oxacalcitriol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 23
Study: 15448489

Group type: EXPERIMENTAL
Intervention: Keratoconus index (KI) calculated from peripheral corneal thickness (PCT) to thinnest corneal thickness (TCT) using a computer-assisted procedure after ultrabiomicroscope (UBM) examination.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Keratoconus severity index (KSI) obtained by videokeratography.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Correlation between KI and KSI.
Number of subjects: 60
Study: 11166966

Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.1 to 10 microM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Phenylephrine (0.1 to 10 microM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Brimonidine (0.01 to 1 microM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Suprathreshold heat stimulus (47 degrees C, 2 s)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Angiotensin II and vasopressin (non-adrenergic vasoconstrictors)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Blood pressure cuff occlusion
Number of subjects: 10
Study: 9539899

Group type: EXPERIMENTAL
Intervention: Active treatment with oral conjugated oestrogens (0.625 mg daily) and cyclic medroxyprogesterone acetate (10 mg daily on Day 14‐27 of each menstrual cycle)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 105
Study: 8005124

Group type: EXPERIMENTAL
Intervention: Captopril pretreatment
Number of subjects: 30
Study: 31705691

Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) administration of tolfenamic acid (4 mg/kg body weight)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) administration of tolfenamic acid (4 mg/kg body weight)
Number of subjects: 10
Study: 29704955

Group type: EXPERIMENTAL
Intervention: Plate osteosynthesis (group A, n=36)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Non-operative management (arm pouch, group B, n=33)
Number of subjects: 69
Study: 27183077

Group type: EXPERIMENTAL
Intervention: Ridge-splitting procedure (test group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional drilling procedure (control group)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 10
Study: 25416143

Group type: COMPARATOR
Intervention: Invisalign group (IG)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Edgewise group (EG)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Edgewise and Invisalign group (EIG)
Number of subjects: 145
Study: 23361051

Group type: EXPERIMENTAL
Intervention: Trebananib (10 mg/kg once weekly) plus FOLFIRI
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 144
Study: 20083537

Group type: EXPERIMENTAL
Intervention: DAS28 measurement by a nurse prior to rheumatologist visit
Number of subjects: 248

Group type: COMPARATOR
Intervention: Usual care (DAS28 measured but not provided to rheumatologists)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: DAS28 measurement by a nurse
Number of subjects: 248

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Baseline DAS28
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: HAQ
Number of subjects: 248
Study: 19919919

Group type: EXPERIMENTAL
Intervention: Peritoneal microdialysis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (38 patients with uncomplicated postoperative course)
Number of subjects: 45
Study: 17018651

Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH) treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 61
Study: 14615476

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50 mg/day for 14 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50 mg/day
Number of subjects: 12
Study: 11033986

Group type: EXPERIMENTAL
Intervention: Peanuts (2092 kJ / 500 kcal)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Peanut butter (rheology control, 2092 kJ / 500 kcal)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Almonds (2092 kJ / 500 kcal)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chestnuts (macronutrient control, 2092 kJ / 500 kcal)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chocolate (sensory control, 2092 kJ / 500 kcal)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low energy preloads
Number of subjects: 24

Group type: COMPARATOR
Intervention: No preload (time control)
Number of subjects: 24
Study: 9179279

Group type: EXPERIMENTAL
Intervention: High-dose Ara-C (HDAC) combined with high dose mitoxantrone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard vincristine, prednisone, anthracycline-based regimen
Number of subjects: 0
Study: 7678711

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 microgram/kg bodyweight)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of dextran 70 and desmopressin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no desmopressin)
Number of subjects: 16
Study: 3468776

Group type: EXPERIMENTAL
Intervention: Dietary restraint
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Severity of previous binge eating and coexistence of high levels of depression and dietary restraint
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Binge eating
Number of subjects: 97
Study: 30075760

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nilotinib
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Imatinib or Nilotinib (optimal response at 12 months)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Imatinib or Nilotinib (optimal response at 6 months)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Imatinib or Nilotinib (optimal response at 3 months)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Imatinib or Nilotinib (optimal response at 3, 6, or 12 months)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nilotinib vs Imatinib
Number of subjects: 59
Study: 27554197

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Non Directive Reflective Listening (NDRL)
Number of subjects: 57
Study: 24832978

Group type: EXPERIMENTAL
Intervention: Cycling with power output alternating between 50 and 100 W every 5 minutes (P2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cycling with power output alternating between 25 and 125 W every 5 minutes (P3)
Number of subjects: 30
Study: 21958662

Group type: EXPERIMENTAL
Intervention: Distraction Osteogenesis (DO)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional Orthognathic Surgery (CO)
Number of subjects: 39
Study: 20039972

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery after lifestyle modifications
Number of subjects: 20

Group type: COMPARATOR
Intervention: Weekly follow-up (Control group)
Number of subjects: 20
Study: 18555912

Group type: EXPERIMENTAL
Intervention: Carbocisteine (1500 mg per day for 1 year)
Number of subjects: 709

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study: 16162626

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C with L-arginine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravenous normal saline with L-arginine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C alone
Number of subjects: 28
Study: 11795726

Group type: COMPARATOR
Intervention: Healthy older adults (n = 17)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Patients with lumbar nerve root compression
Number of subjects: 17
Study: 10422631

Group type: EXPERIMENTAL
Intervention: 60 mg elemental iron with folic acid (0.5 mg) per day for 12 weeks
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 120 mg elemental iron with folic acid (0.5 mg) per day for 12 weeks
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 240 mg elemental iron with folic acid (0.5 mg) per day for 12 weeks
Number of subjects: 3
Study: 7593683

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nondirective supportive therapy
Number of subjects: 30
Study: 2209307

Group type: EXPERIMENTAL
Intervention: Computer algorithms for insulin dosage adjustment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual methods for insulin dosage adjustment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microprocessor device for insulin dosage adjustment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (manual methods)
Number of subjects: 0
Study: 6993113

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide
Number of subjects: 29
Study: 31142350

Group type: EXPERIMENTAL
Intervention: Participation Enabling Care in Nursing (PECAN) intervention
Number of subjects: 578

Group type: COMPARATOR
Intervention: Optimised standard care (usual care and an information session)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: PECAN intervention
Number of subjects: 578
Study: 28523932

Group type: EXPERIMENTAL
Intervention: Repeated testing intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 84
Study: 24994769

Group type: EXPERIMENTAL
Intervention: Rehabilitation according to the American Society of Shoulder and Elbow Therapists' rehabilitation guideline
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 96
Study: 23512711

Group type: EXPERIMENTAL
Intervention: Low-glycemic diet (LoGIX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-glycemic diet (HiGIX)
Number of subjects: 20
Study: 21372744

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study: 19118956

Group type: EXPERIMENTAL
Intervention: Dietary intervention group (DG) receiving approximately 1200 mg of calcium and 7.5 microg of vitamin D3 per day via fortified dairy products and attending biweekly dietary and lifestyle intervention sessions
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Dietary intervention group (DG)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Calcium supplemented group (CaG) receiving a total of 1200 mg calcium per day
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (CG) who continued with their usual diet
Number of subjects: 101
Study: 17360900

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 40,000 IU
Number of subjects: 23

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 23
Study: 15122940

Group type: EXPERIMENTAL
Intervention: Parent-adolescent disagreement regarding behavioral and emotional problems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Child Behavior Checklist (CBCL) and Youth Self-Report (YSR) assessments
Number of subjects: 0
Study: 11409827

Group type: EXPERIMENTAL
Intervention: Lycra garments (Kendall‐Camp UK Ltd) worn for at least 6 hours a day for 6 weeks
Number of subjects: 12
Study: 9403142

Group type: EXPERIMENTAL
Intervention: Selective processing tasks (colour-naming interference and interpretation of ambiguous situations)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 48
Study: 8322058

Group type: EXPERIMENTAL
Intervention: Toothpaste containing sodium fluoride
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Toothpaste containing amine fluoride
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Toothpaste containing sodium monofluorophosphate
Number of subjects: 6
Study: 3618443

Group type: EXPERIMENTAL
Intervention: Ketotifen (open study in 14 asthmatics)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Initial oral provocation tests (OPT)
Number of subjects: 24
Study: 31409486

Group type: EXPERIMENTAL
Intervention: Chemotherapy + Bevacizumab (BEV)
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Chemotherapy + Placebo (P)
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: Both treatment groups (BEV and placebo)
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: Overall analysis of adiposity measures
Number of subjects: 1538
Study: 28103752

Group type: EXPERIMENTAL
Intervention: MynxGrip vascular closure device (VCD)
Number of subjects: 66
Study: 25560100

Group type: EXPERIMENTAL
Intervention: Adjustable single-incision sling
Number of subjects: 156

Group type: COMPARATOR
Intervention: Transobturator sling
Number of subjects: 156
Study: 23025500

Group type: EXPERIMENTAL
Intervention: Positive stereotype exposure (e.g., 'Asians are good at math', 'women are nurturing')
Number of subjects: 5

Group type: COMPARATOR
Intervention: No stereotype exposure
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Independent self-construal
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Interdependent self-construal
Number of subjects: 5
Study: 21319896

Group type: EXPERIMENTAL
Intervention: ModerateDrinking.com (MD) combined with Moderation Management (MM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Moderation Management (MM) alone
Number of subjects: 80
Study: 19842825

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI) for resolution of ambivalence and sex risk reduction planning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMI with biological feedback based on testing for STIs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonintervention control (standard HIV information dissemination)
Number of subjects: 0
Study: 16904542

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with AVJ ablation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT) without AVJ ablation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT) in sinus rhythm (SR) patients
Number of subjects: 48
Study: 15005820

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10